Oncology Sponsored Global oncology innovation from Hengrui Pharma Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
News AbbVie bids to join the BCMA crowd with etentamig AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
News ESMO26: Ris-rez offers hope of osteosarcoma breakthrough There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.
News ESMO26: AZ's claudin ADC doubles survival in GI cancers AstraZeneca's CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers reveals a 53% reduction in the risk of death.
News ESMO26: Roche's KRAS drug tops approved drugs in NSCLC In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met high expectations, with a head-to-head win over Lumakras and Krazati.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.